市場調査レポート
商品コード
1422881
左心房付属器閉鎖装置市場:製品、エンドユーザー、地域別、2024年~2032年Left Atrial Appendage Closure Devices Market by Product (Endocardial LAA Devices, Epicardial LAA Devices), End User (Hospitals, Ambulatory Surgery Centers, and Others), and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
左心房付属器閉鎖装置市場:製品、エンドユーザー、地域別、2024年~2032年 |
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2~3営業日
|
世界の左心房付属器閉鎖装置市場規模は2023年に15億米ドルに達しました。今後、IMARC Groupは、市場が2032年までに63億米ドルに達し、2024年から2032年の間に16.85%の成長率(CAGR)を示すと予測しています。心房細動(AFib)の有病率の上昇、心血管障害(CVDs)に罹患しやすい高齢者人口の増加、継続的な製品の進歩と技術革新は、市場を牽引する主な要因のいくつかです。
左心房付属器閉鎖装置(LAAC)は、非弁膜症性心房細動(AFib)患者の脳卒中リスクを低下させるために心臓に植え込まれる医療機器です。左心房付属器(LAA)は心臓の筋壁にある小さな袋状の構造で、心房細動患者では血栓の発生源となり脳卒中を引き起こす可能性があります。LAACデバイスは、血栓の形成を予防し、脳卒中のリスクを軽減するために、LAAを永久的に閉鎖するように設計されています。LAACデバイスは低侵襲(MI)手技で植え込まれ、通常、腕や鼠径部に小さな切開創を入れ、カテーテルを用いて挿入されます。これらのデバイスは、抗凝固薬を服用できない、あるいはこれらの薬による出血合併症のリスクが高い心房細動患者の間で広く普及しています。
不健康な食習慣、喫煙、飲酒、座りっぱなしのライフスタイルの広まりを背景とした心房細動の有病率の上昇が、主に世界市場の成長を牽引しています。これに加えて、心血管障害(CVDs)になりやすい老年人口の増加、心房細動に関連するリスクや合併症に関する消費者の懸念の高まり、代替治療オプションの利用可能性に関する認知度の拡大が、市場成長を促しています。さらに、製品の安全性と有効性の観点から閉鎖器具の技術的進歩が著しく、回復時間を短縮し患者の快適性を向上させるために低侵襲閉鎖器具の開拓に重点が置かれていることが、市場に有益な成長機会をもたらしています。これと同時に、電気生理学的手技の登場とインターベンション治療および診断経路の大幅な改善が相まって、市場の成長に寄与しています。これに加えて、ヘルスケア・インフラの急速な拡大、ヘルスケア・サービスへのアクセスの改善、低侵襲閉鎖器具の人気の急上昇、各国政府による多数の啓蒙キャンペーンの開始、償還政策の利用可能性などが市場拡大に寄与しています。さらに、製品革新のための広範な研究開発(R&D)活動、心房インターベンション製品の承認数の増加、臨床試験数の増加、ロボット支援閉鎖デバイスなどの新技術の採用が市場成長にプラスの影響を与えています。
The global left atrial appendage closure devices market size reached US$ 1.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.3 Billion by 2032, exhibiting a growth rate (CAGR) of 16.85% during 2024-2032. The escalating prevalence of atrial fibrillation (AFib), the growing geriatric population prone to cardiovascular disorders (CVDs), and ongoing product advancements and innovations represent some of the key factors driving the market.
Left atrial appendage closure devices (LAAC) are medical devices that are implanted in the heart to lower the risk of stroke in patients with non-valvular atrial fibrillation (AFib). The left atrial appendage (LAA) is a small pouch-like structure located in the muscle wall of the heart, which can be a source of blood clots, leading to stroke in AFib patients. LAAC devices are designed to permanently close off the LAA to prevent the formation of blood clots and reduce the risk of stroke. They are implanted via minimally invasive (MI) procedures, typically using a catheter that is inserted through a small incision placed in the arm or groin region. These devices are widely popular among AFib patients who cannot take anticoagulant medications or are at high risk of bleeding complications from these medications.
The rising prevalence of AFib, on account of the widespread adoption of unhealthy eating habits, smoking, drinking, and sedentary lifestyles, is primarily driving the global market growth. Besides this, the growing geriatric population prone to cardiovascular disorders (CVDs), the escalating consumer concerns regarding risks and complications associated with AFib, and the expanding awareness about the availability of alternative treatment options are impelling the market growth. Moreover, significant technological advancements in closure devices in terms of the safety and efficacy of the product and the intensive emphasis on developing minimally invasive closure devices to reduce recovery time and improve patient comfort are presenting remunerative growth opportunities for the market. Concurrent with this, the advent of electrophysiology procedures, combined with considerable improvements in interventional treatments and the diagnosis pathway, is contributing to the market growth. In addition to this, rapid expansion in the healthcare infrastructure, better access to healthcare services, the surging popularity of minimally invasive closure devices, the launch of numerous awareness campaigns by governments of various countries, and the availability of reimbursement policies are aiding in market expansion. Furthermore, extensive research and development (R&D) activities for product innovation, a rising number of atrial intervention product approvals, an increasing number of clinical trials, and the adoption of new technologies, such as robotic-assisted closure devices, are positively impacting the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global left atrial appendage closure devices market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product, and end user.
Endocardial LAA Devices
Epicardial LAA Devices
The report has provided a detailed breakup and analysis of the left atrial appendage closure devices market based on the product. This includes endocardial LAA devices and epicardial LAA devices. According to the report, endocardial LAA devices represented the largest segment.
Hospitals
Ambulatory Surgery Centers
Others
A detailed breakup and analysis of the left atrial appendage closure devices market based on the end user has also been provided in the report. This includes hospitals, ambulatory surgery centers, and others. According to the report, hospitals accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for left atrial appendage closure devices. Some of the factors driving the North America left atrial appendage closure devices market included a growing number of atrial fibrillation (Afib) cases, a rise in the geriatric population, and innovative technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global left atrial appendage closure devices market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, AtriCure Inc., Boston Scientific Corporation, Cardia Inc., Lepu Medical Technology (Beijing) Co. Ltd., LifeTech Scientific, etc.